Breaking Down Scope 1, 2, and 3 Emissions for Pharmaceutical Manufacturers

Breaking Down Scope 1, 2, and 3 Emissions for Pharmaceutical Manufacturers

Across the pharmaceutical industry, sustainability has evolved from an aspiration to an expectation. Every major pharma company now publishes annual climate targets and partners with suppliers who can help achieve them. But behind those commitments, you’ll often see terms like Scope 1, Scope 2, and Scope 3 emissions; technical language that can leave many people wondering: Where do these numbers come from, and what do they mean for manufacturers and suppliers?  We’re going to break it down simply.

The Greenhouse Gas (GHG) Protocol: A Common Language

To measure and manage carbon emissions consistently across industries, most organizations use the Greenhouse Gas (GHG) Protocol, a global accounting standard developed by the World Resources Institute (WRI) and the World Business Council for Sustainable Development (WBCSD).  It divides all emissions from business activity into three categories, or “scopes,” based on how directly an organization controls them.

Scope 1: Direct Emissions

These are emissions from sources a company owns or controls directly.
In biopharma, this might include:

• Fuel burned in facility boilers or backup generators
• Company-owned vehicles
• On-site process or laboratory emissions

If it’s a physical emission from your own operations, it’s considered Scope 1.

Scope 2: Indirect Energy Emissions

Scope 2 covers emissions from purchased energy, like the electricity, steam, heat, or cooling that your company buys to run facilities and cleanrooms.

You don’t produce the emissions yourself, but you’re responsible for them because your operations rely on that energy.  That’s why many pharma companies invest in renewable electricity contracts or onsite solar power in order to reduce Scope 2 emissions.

Scope 3: Value Chain Emissions (Upstream and Downstream)

Scope 3 is where things get big and complicated.  These are all other indirect emissions that occur throughout your value chain, both upstream (from your suppliers) and downstream (from customers using or disposing of your products).

For biopharma, typical upstream Scope 3 categories include:

• Purchased raw materials and components (like tubing, fittings, and filters)
• Packaging materials
• Transportation and logistics
• Contract manufacturing and research services
• Business travel and employee commuting

And on the downstream side:

• Product distribution
• End-of-life treatment or waste management of materials and packaging

For most pharma companies, Scope 3 represents 70–90% of total emissions, which is why suppliers now play such a critical role in decarbonization.

Why Suppliers Matter So Much

Pharma manufacturers can control their facilities (Scope 1 & 2), but they can’t meet carbon targets alone.  The largest portion of their environmental impact sits in the materials they purchase, which include polymers, assemblies, packaging, and logistics.  That means progress depends on supplier collaboration.

To meet corporate sustainability goals, biopharma companies now evaluate whether their suppliers can provide:

• Certified sustainable materials (like ISCC PLUS mass-balance certified resins)
• Transparency and documentation to support Scope 3 reporting
• Sustainability strategies aligned with EcoVadis, SBTi, and GHG reduction targets

In short, when suppliers make their own operations and materials more sustainable, they directly reduce their customers’ Scope 3 footprint.

How ecobio™ Supports Scope 3 Progress

ecobio™ was created to help biopharma companies achieve sustainability objectives through their supply chain, without compromising process performance.

By manufacturing components from mass-balance certified resins, ecobio™ enables renewable feedstocks to be attributed to existing high-purity polymers.  This approach provides:

• Verified traceability through ISCC PLUS certification
• Alignment with Scope 3 Category 1 (Purchased Goods and Services) reporting
• No change to product validation, materials, or regulatory filings

That means manufacturers can demonstrate measurable supply-chain improvements without re-engineering their validated systems, a rare win-win for sustainability and compliance.

Putting It All Together

Key Takeaways

• The GHG Protocol divides emissions into Scopes 1, 2, and 3 to create a consistent global framework.
• Scope 3 comes from purchased goods and supply chain activity and is the largest share of emissions for most biopharma companies.
• Suppliers are central to decarbonization, providing the materials and data that make Scope 3 progress measurable.
• ecobio™ helps customers act now, with certified, renewable-attributed components that support sustainability reporting and ESG goals without disrupting validated systems.